Galectin-3 Serum Levels Could Help Clinicians Screen for Salivary Gland Tumor Patients

Document Type: Research Articles

Authors

1 Oral and Dental Disease Research Center, School of Dentistry, Shiraz University of Medical Sciences, Shiraz, Iran.

2 Shiraz Institute for Cancer Research, School of Dentistry, Shiraz University of Medical Sciences, Shiraz, Iran.

3 Undergraduate Student, School of Dentistry, Shiraz University of Medical Sciences, Shiraz, Iran.

Abstract

analysis was performed on serum specimens from 105 patients with salivary gland cancer and 56 healthy persons.
Methods: Enzyme-linked immunosorbent assay (ELISA) was used to measure levels of galectin-3 (GAL-3). Serum
levels were compared between patients with salivary gland tumors and healthy control. A total of 105 patients were
enrolled in the study (55 men, 50 women). Result: Mean age was45.5 years. Thirty-nine patients with malignant and
66 cases with benign tumors were compared with 56 healthy participants with a mean age of 51.7. No statistically
significant differences were observed when comparing GAL-3 serum levels between malignant and benign salivary gland
tumor patients, but a statistically significant difference was found between case and control patients with p-values of
0.02. Serum levels of galectin-3 protein were elevated in patients with salivary gland cancer compared with the healthy
population. Conclusion: The difference between benign and malignant tumor patients was significant, but revealed
no clinic pathological characteristics in malignant tumors. To the best of the authors’ knowledge, this is the first time
a study suggests that GAL-3 serum levels could help clinicians screen for salivary gland cancer.

Keywords

Main Subjects